Ronald Blue Trust, Inc. Akero Therapeutics, Inc. Transaction History
Ronald Blue Trust, Inc.
- $7.7 Billion
- Q4 2024
A detailed history of Ronald Blue Trust, Inc. transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 13 shares of AKRO stock, worth $658. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13
Previous 71
81.69%
Holding current value
$658
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding AKRO
# of Institutions
210Shares Held
74.3MCall Options Held
321KPut Options Held
558K-
Wellington Management Group LLP Boston, MA7.38MShares$374 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY6.86MShares$348 Million3.11% of portfolio
-
Janus Henderson Group PLC London, X06.03MShares$306 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$283 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$265 Million5.21% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.35B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...